scispace - formally typeset
M

Marc A. Pfeffer

Researcher at Brigham and Women's Hospital

Publications -  815
Citations -  143710

Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.

Papers
More filters
Journal ArticleDOI

Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus

Eldrin F. Lewis, +11 more
- 01 Aug 2015 - 
Journal ArticleDOI

Angiotensin-converting enzyme inhibition in congestive heart failure: Benefit and perspective

Marc A. Pfeffer, +1 more
- 01 Sep 1993 - 
TL;DR: Key studies that have documented the efficacy of ACE inhibitors in improving clinical outcome for patients with overt congestive heart failure, as well as for those with asymptomatic left ventricular dysfunction are reviewed.
Journal ArticleDOI

Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.

Eldrin F. Lewis, +17 more
- 01 Mar 2018 - 
TL;DR: Black patients with HFpEF have a higher HF hospitalization risk than nonblack patients, but spironolactone is similarly effective and safe in both groups, according to self-described black and nonblack race.
Journal ArticleDOI

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)

Shelby D. Reed, +10 more
- 01 Aug 2005 - 
TL;DR: For most patients at high risk after MI, the availability of generic captopril confers a cost advantage over valsartan because of lower medication costs, which will be smaller or nonexistent in settings where brand-name ACE inhibitors are prescribed.
Journal ArticleDOI

Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.

Eileen O'Meara, +14 more
- 01 Jun 2005 - 
TL;DR: To evaluate the effect of the angiotensin receptor blocker candesartan on patients' perception of symptoms, using the McMaster Overall treatment evaluation (OTE), in a broad spectrum of patients with chronic heart failure (CHF).